Actualités
Galeon Fundraising 2026: Why Invest in the Next-Generation EHR?
Everything you need to know about the equity fundraising campaign for the Galeon National Health Record
Updated on
9/6/2026
Summary
The essentials in 30 seconds
Introduction
The French hospital system remains fragmented. Patient data does not circulate between facilities, and according to the French Hospital Federation, around 30% of medical procedures are deemed unnecessary or redundant because of these scattered records. This waste carries a considerable human and financial cost.
This is the problem Galeon has addressed since 2016 with the first patient record shared across hospitals. The solution is not a promise: it is already deployed in 19 French public hospitals and used daily by more than 10,000 caregivers, from the Caen University Hospital to the Toulon Hospital Centre.
Galeon has already built the infrastructure and validated its product in real-world conditions; what is missing today is the capital to deploy it at national scale. That is the purpose of the investment campaign open until 23 June 2026.
This article breaks down the mechanics of this raise, what it concretely funds, the value for each investor profile, and above all the real risks to weigh before any decision.
What are the terms of the Galeon 2026 fundraising?
The Galeon investment campaign is an equity operation: you buy shares and become a shareholder of the company. The key parameters are public and verifiable in the investor pack.
- Financial product: equity shares, no debt and no token
- Available capital: 6% of the company's equity
- Raise target: €3 million
- Current valuation: €50 million
- Minimum ticket: €1,000
- Tax eligibility: PEA and PEA-PME
- Closing date: 23 June 2026
PEA-PME eligibility is an often-underestimated point: subject to holding-period conditions, it allows reduced taxation on capital gains. It is a scheme reserved for European SMEs meeting specific size criteria.
What will the raised money be used for?
The raise funds four concrete initiatives, all geared toward scaling up. Galeon has already proven its product works; the challenge now is deployment.
Connecting more hospitals
The Galeon EHR is used across 19 interconnected hospitals. Part of the funds will accelerate deployment to new facilities, with each signed hospital increasing recurring SaaS revenue.
Steering health policy at national scale
The ambition is to become the national health record. By replacing fragmented systems with a single solution, Galeon targets regional analytics: monitoring health risks, admissions, trends and prevention across an entire territory.
Building a medical AI copilot
Thanks to the structured data collected, Galeon is developing AI decision-support tools. Some functions are already in production (LAP-certified secure prescription, prescription recognition, automatic PMSI/CCAM billing), others are coming (automatic hospitalization reports, smart biomarkers for sepsis or hemorrhage).
Exporting internationally
Beyond France, projects are underway in Switzerland, Luxembourg and Belgium. Part of the raise will strengthen the product and deployment teams to accelerate this expansion.
What is the value for each type of investor?
For the individual investor
The €1,000 entry ticket makes the operation accessible. PEA-PME eligibility offers a tax lever for French tax residents. You invest in a company whose product is already deployed and generating revenue, which reduces execution risk compared with a pre-revenue startup.
For the professional / HealthTech investor
Galeon checks the boxes of a mature HealthTech case: HDS and ISO 27001 certified product, proprietary technology (Blockchain Swarm Learning®), large addressable market (25,000 hospitals in Europe) and a recurring-revenue SaaS model. Its positioning on health data sovereignty aligns with European regulatory priorities.
For the caregiver or hospital CIO
Investing in Galeon also means supporting an infrastructure you use daily. For a hospital decision-maker, it is an alignment of interests: the company's valuation depends directly on tangible improvements in care and reduced administrative burden.
Galeon vs traditional HealthTech investment: the comparison
| Criterion | Galeon 2026 raise | Typical early-stage HealthTech startup |
|---|---|---|
| Maturity stage | Product deployed in 19 hospitals in production | Often at prototype or pre-deployment stage |
| Revenue | Existing recurring SaaS revenue | Frequently pre-revenue or marginal revenue |
| Entry ticket | Accessible from €1,000 | Often reserved for funds (high tickets) |
| Tax advantage | PEA and PEA-PME eligible | Variable, rarely structured for individuals |
| Product validation | HDS, ISO 27001, LAP certified | Certifications often still pending |
| Differentiating tech | Proprietary Blockchain Swarm Learning® | Often dependent on third-party building blocks |
| Addressable market |
